This activation leads to IRF3 phosphorylation and production of type I interferons (e.g., IFN-β) and inflammatory cytokines (e.g., CXCL10, IL-6), enhancing the tumor’s immune profile. This evidence concerns the gene CXCL10 and neoplasm.